BiondVax Pharma (BVXV) Announces Planned Launch of Multimeric-001 Phase 2

September 2, 2015
Tools
  • Print

BiondVax Pharma (NASDAQ: BVXV) announced the intent of the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to launch a new phase 2 trial to be held in the United States in the 2015-16 timeframe. The trial will examine the use of BiondVax's universal flu vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, which would be administered several weeks before a pandemic vaccine. The trial will be a collaboration between BiondVax and the National Institute of Allergy and Infectious Diseases.

The trial will assess the ability of M-001 in humans to serve as a pandemic primer to the H7N9 avian pandemic vaccine, by enhancing protective immunity to these highly pathogenic avian influenza H7 strains. It will also look to strengthen previous clinical and pre-clinical findings on M-001 priming capacity to other seasonal and pandemic strains.

Typically, a strain-specific flu vaccine for a pandemic outbreak takes 4-6 months to manufacture, a period during which the virus can spread rapidly, causing high levels of illness and mortality. Stockpiling of M-001 as a pandemic primer would enable vaccination schedules to start immediately upon any pandemic declaration.

BiondVax is currently producing the M-001 vaccine batch for this clinical trial.

Ron Babecoff, BiondVax's President and CEO, commented, "The recognition of the potential of our technology by a foremost public health authority in the United States, is a significant milestone in our clinical development program. This trial will assess our vaccines' ability to be used as the stockpiled flu vaccine for pandemic protection. The scenario is that immediately following a flu pandemic outbreak of any strain, our vaccine could be used from day zero, saving multiple lives and limiting the wild spread of a flu pandemic. This collaboration with NIAID brings us a significant step closer to our Phase 3 clinical trial."

Tamar Ben-Yedidia, BiondVax's Chief Scientific Officer, commented, "This important trial is examining the use of M-001 in the event of an H7 avian influenza outbreak. It is complementary to a previous clinical trial in the elderly that concluded successfully, showing enhanced immunogenicity against the H1N1 swine pandemic virus in participants that received our M-001 vaccine as primer. This study is also complementary to our upcoming European clinical trial in which the M-001 will serve as a primer to the H5N1 avian pandemic vaccine."

Press Releases
  • First Investigational All Injectable Long Acting HIV Combination Regimen Study Results at 32 Weeks Announced
  • Ginkgo Bioworks To Purchase 100 Million Base Pairs Of Synthetic DNA From Twist Bioscience To Meet Growing Customer Demand For Biological Manufacturing
  • Genomics England Selects Cognizant as a Technology Partner for the Department of Health's 100,000 Genomes Project
  • Medrobotics Closes $25 Million Financing
  • Neuravi Announces First Patient Treated in International Pivotal Clinical Trial of Novel Stent Retriever for Acute Ischemic Stroke
  • More Press Releases
Featured Jobs
> Need a job? Need to hire? Visit our jobs site.